Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
OPEN BMJ (Clinical research ed.) | 23 Mar 2018
D Abrahami, A Douros, H Yin, OHY Yu, C Renoux, A Bitton and L Azoulay
To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence of inflammatory bowel disease in patients with type 2 diabetes.
* Data courtesy of Altmetric.com